Economic implications for use of nucleic acid amplification test (NAAT) technology in different clinic settings (May 2013 to January 2015, 21 months)
| Row | Genitourinary medicine | Primary care | Total | ||||
|---|---|---|---|---|---|---|---|
| Symptomatic | Asymptomatic | Symptomatic | Asymptomatic | ||||
| Group 1 | Group 2 | Group 3 | Group 4 | ||||
| All women in the study (tested for STI plus TV) | Positive, TMA (percentage) | A | 24 (4.5%) | 27 (1.7%) | 94 (2.7%) | 41 (1.1%) | 186 (2.0%) |
| Total | B | 530 | 1584 | 3499 | 3573 | 9186 | |
| Women tested under current protocol | Positive, TMA | C | 22 | 1 | 62 | 12 | 97 |
| Positive, wet mount/culture | D | 12 | 1 | 17 | 2 | 32 | |
| Total tested | E | 485 | 17 | 2133 | 789 | 3424 | |
| Difference in diagnoses | F=A–D | 12 | 26 | 77 | 39 | 154 | |
| Positivity | TMA test | G=C/E | 4.5% | 5.9% | 2.9% | 1.5% | 2.8% |
| Wet mount/culture | H=D/E | 2.5% | 5.9% | 0.8% | 0.3% | 0.9% | |
| Baseline (current situation) | Current cost | I=E×£7.93 | £3846 | £135 | £16 915 | £6257 | £27 152 |
| Cost per positive (£7.93) | J=I/D | £321 | £135 | £995 | £3128 | £849 | |
| Scenario 1 TMA costs £7.62 using existing diagnostic platform | Total cost (TMA test) | K=B×£7.62 | £4039 | £12 070 | £26 662 | £27 226 | £69 997 |
| Difference in cost | L=K–I | £193 | £11 935 | £9748 | £20 969 | £42 845 | |
| Cost per additional positive | M=L/F | £16 | £459 | £127 | £538 | £278 | |
| Cost per positive | N=K/A | £168 | £447 | £284 | £664 | £376 | |
| Scenario 2 TMA costs £15.19, different test platform | Total cost (TMA test) | O=B×£15.19 | £8051 | £24 061 | £53 150 | £54 274 | £139 535 |
| Difference in cost | p=O–I | £4205 | £23 926 | £36 235 | £48 017 | £112 383 | |
| Cost per additional positive | Q=P/F | £350 | £920 | £471 | £1231 | £730 | |
| Cost per positive | R=O/A | £335 | £891 | £565 | £1324 | £750 | |
TMA, transcription-mediated amplification.